Back to Awarded Treatment Trials


Awarded Trial: 01-106

Grant ID

01-106

Illness

Bipolar Disorder

Primary Drug/Intervention

Chromium Picolinate

Primary Dosage

600 mg - 800 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Amann

Sample Size

30

Duration of Study Period for Each Subject

3 weeks, with optional 2 year follow up

Outcome Measurements

CGI-BP, HAM-D, MADRS, YMRS

Results

At enrollment 23 patients had a depressive syndrome and seven were euthymic. Depressed patients experienced a 26% reduction in HAM-D scores and a similar reduction in MADRS scores. About 30% of patients were considered to be responders (>50% reduction in depression ratings). Seven patients remained on the treatment for one year and four for two years. The number of effective episodes for these patients decreased relative to the period prior to study entry.

Publication

N/A

Link

N/A

PI Name

Benedikt Amann

Degree

MD

Center

Dept. of Psychiatry and Psychotherapy

Institution

Ludwig-Maximillians Universitaet

Address

Nussbaumstr. 7, Ward C2

City or Town

Munich

State or Province

N/A

Zip or Postal Code

80336

Country

Germany

Email Address

benedikt.amann@med.uni-muenchen.de